Guangzhou Xinyi Pharmaceutical Co., Ltd. (referenced as Xinyi Pharmaceutical) has recently submitted its listing application to the main board of the Hong Kong Stock Exchange, just two months after its previous filing lapsed. Since its founding, the company has completed six financing rounds, raising approximately 291 million yuan in total, with investors including Guangyao Venture Capital, Yuexiu Danlu, Zhejiang Venture Capital, Zhuhai Fund Phase III, and Shaoguan Limited Partnership. Following its Series C financing in November 2025, the company's implied valuation reached 1.53 billion yuan. However, unlike typical innovative drug companies focused on molecular discovery, Xinyi Pharmaceutical primarily concentrates on improved new drugs, seeking differentiation in areas like drug delivery methods and alternative formulations. Yet, the company's two core products are currently only in Phase II clinical trials, with clinical efficacy data yet to be disclosed. With significant uncertainties remaining, can the company truly convince market investors based solely on its potential?
Accumulated losses exceed 400 million yuan; core products not yet commercialized
According to its prospectus, Xinyi Pharmaceutical was founded in 2007 and is a clinical-stage pharmaceutical company. Based on previously approved active pharmaceutical ingredients (APIs), the company utilizes alternative formulation and drug delivery technologies to develop and commercialize improved new drugs. Currently, it has no commercialized products, with revenue primarily coming from CRO services and MAH operations. In its MAH business, the company terminated sales of its propofol emulsion injection in 2024, now relying on a single product: esomeprazole magnesium extended-release capsules (sold in the US, with product rights from a third party, commissioned to a CMO for production and distribution, unrelated to core products). Financially, for the fiscal years 2024, 2025, and the five months ending May 31, 2026, the company generated revenues of 49.026 million yuan, 55.238 million yuan, and 16.567 million yuan, respectively, with corresponding gross margins of 33.7%, 23.4%, and 19.8%. During these periods, it recorded net losses of approximately 147.1 million yuan, 110.9 million yuan, and 197.2 million yuan, accumulating total losses of 455.2 million yuan over the reporting period. The company expects to continue incurring net losses in the foreseeable future. Operating losses primarily stem from R&D program expenses and administrative costs related to operations. R&D expenses for the reporting periods were 16.41 million yuan, 38.18 million yuan, and 18.96 million yuan, mostly directed toward its two core products. In terms of cash flow, net cash used in operating activities was approximately 15.29 million yuan, 66.52 million yuan, and 30.8 million yuan for the same periods. As of May 31, 2026, the company's cash and cash equivalents were only about 103 million yuan, with a net current liability of 573 million yuan and a net liability of 533 million yuan. Based on the current cash burn rate, existing funds can only sustain approximately eight months of operations without additional financing.
Soluble microneedle technology: innovative drug delivery achieving painless, minimally invasive administration
Unlike typical innovative drug companies focusing on molecular discovery, Xinyi Pharmaceutical's pipeline strategy selects indications where existing traditional formulations have limitations (such as invasiveness, poor patient compliance, or unfavorable pharmacokinetic profiles). It applies drug formulation technologies to address these challenges, breaking through traditional delivery routes to improve treatment efficacy, patient compliance, and clinical utility. The company has two major drug formulation technology platforms: soluble microneedle technology and nasal inhalation technology. Based on these, it has independently developed products like dexmedetomidine hydrochloride microneedle patch (DHMP) and nasal inhalation preparation XJN010. The soluble microneedle technology uses micron-sized needle arrays to penetrate the skin's stratum corneum, releasing the drug as the needles dissolve, achieving painless, minimally invasive transdermal delivery designed to replace traditional injections. Xinyi Pharmaceutical's core product, DHMP, is intended for pre-surgical sedation in children and adults. The company launched a Phase IIa clinical trial for pediatric indications in August 2025, completing the study in June 2026. A Phase II clinical trial for adult indications began in March 2026. This product is China's first approved soluble microneedle transdermal drug patch for clinical trials. In terms of commercialization, DHMP is designed as a more comfortable non-intravenous sedation option for perioperative and invasive procedures, initially targeting hospital channels including anesthesiology, pain management, endoscopy centers, and pediatrics, focusing on scenarios where non-intravenous delivery is advantageous. However, given its innovative delivery method, DHMP's final efficacy and clinical benefits remain unclear, and the safety, efficacy, and regulatory approval of its subsequent clinical trials are uncertain. Beyond DHMP, the company is expanding into endocrine therapy, advancing microneedle patch XJN1102 for diabetes and weight control, with plans to submit IND applications to the NMPA and FDA in the fourth quarter of 2026. In recent years, microneedles have garnered significant attention in the pharmaceutical industry and academia as a key formulation technology for innovative drugs. However, their development involves multi-disciplinary integration with high technical barriers, facing challenges like drug delivery system compatibility, stability, drug loading efficiency, release kinetics, and intradermal absorption characteristics. Microneedles are not suitable for all drugs or indications and require tailored development based on drug physicochemical properties, dosing frequency, and clinical needs. In terms of drug loading, microneedles only carry the drug in the needle tip shell, resulting in low loading capacity, which may not meet the therapeutic dose requirements for some drugs. In production, the tiny size of microneedles significantly raises the precision requirements for industrial scale-up. While cosmetic microneedle products are already on the market, large-scale production and sterile packaging of drug microneedle patches still face significant challenges. Additionally, microneedle use requires puncturing the skin's stratum corneum, leading to strict regulatory approvals, and there are currently no targeted quality standards or policies. All these factors will be hurdles Xinyi Pharmaceutical must overcome when commercializing its products.
Nasal inhalation preparations: targeting blue ocean markets like Parkinson's disease
Nasal inhalation preparations are another important technological direction for Xinyi Pharmaceutical, showing particular advantages in treating central nervous system diseases. The nasal cavity's unique anatomical structure connects to the central nervous system above and the respiratory tract below, serving as a barrier against pathogens while providing a convenient pathway for drug entry into the brain. The nasal mucosa is rich in blood vessels and highly permeable, creating favorable conditions for drug absorption. Drugs absorbed through the nasal cavity can bypass the blood-brain barrier to directly enter the brain, typically exerting stronger central nervous system pharmacological effects. Therefore, nasal drug delivery is increasingly used in treatments for central analgesia, sedation, antiemesis, antidepressants, and anti-epilepsy. Currently, the application of nasal drug delivery in central nervous system disease treatment has become a hot spot in industry R&D, but only a few related products are on the market in China, such as diazepam nasal spray for epilepsy and sumatriptan nasal spray for migraines, leaving a vast market space. Xinyi Pharmaceutical's second core product, XJN010, is a nasal inhalation preparation for on-demand treatment of "off" episodes in Parkinson's disease patients. "Off" episodes are characterized by the recurrence or worsening of motor symptoms previously controlled by medication. Currently, there are no approved therapies for this symptom in China, indicating a clear clinical need. XJN010 completed Phase II clinical trials in China in April 2026. According to Frost & Sullivan data, it is the only investigational product in China approved for clinical trials targeting "off" episodes in Parkinson's disease. In the US, the product received IND approval in February 2026, allowing direct entry into Phase II clinical trials, with plans to initiate related studies in the third quarter of 2026. Additionally, the company has established a clear pipeline in indications requiring rapid symptom relief, such as preclinical-stage vasoconstrictor nasal inhalation preparation XJN026, intended for acute treatment of migraines with or without aura in adults and pediatric patients aged 6 to 17. It has started a Phase I clinical trial in China in April 2026 and is preparing to submit an IND application to the FDA. Another nasal preparation for chemotherapy-induced vomiting, XJN2503, is planned for IND submission to the NMPA in the fourth quarter of 2026. Both are ahead of competitors. However, nasal drug delivery also has inherent limitations. Nasal mucosa absorption is influenced by drug properties and nasal cavity conditions, leading to instability. Some drugs may irritate the mucosa, with long-term use posing risks of damage. The nasal cavity is prone to contamination, increasing the risk of infection during administration. Not all drugs are suitable for this route, as some are easily degraded by enzymes, have difficulty penetrating the mucosa, or are too irritating. The small surface area of the nasal cavity limits single-dose volume, and the mucus layer and mucosal enzymes can hinder absorption, potentially causing systemic side effects. The complex anatomy of the nasal cavity may also affect patient compliance with long-term administration. The company's prospectus also acknowledges that clinical trials of nasal drug delivery for central nervous system conditions have in some cases been interrupted or terminated due to insufficient efficacy. The efficacy and clinical benefits of XJN010 remain unknown. Typically, Phase I studies are designed to assess safety, tolerability, and pharmacokinetics, not to establish efficacy. Although DHMP and XJN010 have completed Phase IIa or Phase II clinical studies, the clinical study reports are not yet finalized, and no efficacy data is available. There is no guarantee that the safety and pharmacokinetic data observed so far will predict the results of subsequent trials.
Summary
Overall, Xinyi Pharmaceutical is rushing to the Hong Kong Stock Exchange with two innovative formulation platforms, targeting blue ocean markets with clear clinical needs: transdermal drug delivery and central nervous system delivery. Its core product, DHMP, is China's first soluble microneedle patch to enter clinical trials, while XJN010 is advancing concurrently in China and the US, capturing the niche segment of Parkinson's disease "off" episodes without competitors. However, the company has not yet commercialized any products, and its financial situation is becoming increasingly strained. With accumulated losses exceeding 450 million yuan over the reporting period and existing cash sufficient for only about eight months of operations, future clinical progress heavily depends on IPO proceeds or another round of external funding. At the same time, both core products are in early-stage clinical development, with efficacy data undisclosed and subsequent validation uncertain. On the commercialization front, the company faces multiple challenges, including large-scale production, quality control, and the absence of regulatory standards. For the capital market, with an unclear commercialization outlook, discussing valuation at this point may be premature.
Comments